^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BMS-986156

    i
    Other names: BMS-986156, BMS 986156
    Associations

    News

    Trials
    Company:
    BMS
    Drug class:
    GITR agonist
    Related drugs:
    Associations

    News

    Trials
    7ms
    Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial. (PubMed, J Immunother Cancer)
    Actualization of a patient-specific I-O combination treatment selection strategy is feasible, however, determination of de novo integral biomarker thresholds of novel I-O targets to facilitate effective treatment of PD-1-refractory cancer remains fraught. These data emphasize the difficulty of integral biomarker development for I-O in translating from immunotherapy treatment-naïve biospecimens to the selection of patients in the PD-1-refractory state.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • LAG3 (Lymphocyte Activating 3) • TNFA (Tumor Necrosis Factor-Alpha) • IDO1 (Indoleamine 2,3-dioxygenase 1) • CSF1R (Colony stimulating factor 1 receptor) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • linrodostat (BMS-986205) • cabiralizumab (BMS-986227) • relatlimab (BMS-986016) • BMS-986156 • lirilumab (BMS-986015) • urelumab (BMS-663513)
    8ms
    BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov)
    P1/2, N=51, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Aug 2027 --> Apr 2025 | Trial primary completion date: Aug 2027 --> Apr 2025
    Trial completion • Trial completion date • Trial primary completion date • Tumor mutational burden
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156
    1year
    Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies. (PubMed, J Immunother Cancer)
    BMS-986156 was well-tolerated with ipilimumab, nivolumab, with or without SABR. Outcomes were encouraging in this population, as more than half of patients had stable disease/partial response.
    P1/2 data • Journal • Metastases
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156
    1year
    BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov)
    P1/2, N=68, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2027
    Trial completion date • Trial primary completion date • Tumor mutational burden • Metastases
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156
    over2years
    BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov)
    P1/2, N=68, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Aug 2023 --> Aug 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
    Trial completion date • Trial primary completion date • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156
    over2years
    Pharmacodynamic activity of BMS-986156, a glucocorticoid-induced TNF receptor-related protein agonist, alone or in combination with nivolumab in patients with advanced solid tumors. (PubMed, ESMO Open)
    Despite the robust evidence of peripheral PD activity of BMS-986156, with or without nivolumab, limited evidence of T- or NK cell activation in the tumor microenvironment was observed. The data therefore explain, at least in part, the lack of clinical activity of BMS-986156 with or without nivolumab in unselected populations of cancer patients.
    PK/PD data • Journal • Combination therapy • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    PD-L1 expression
    |
    Opdivo (nivolumab) • BMS-986156
    almost3years
    BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers (clinicaltrials.gov)
    P1/2, N=68, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
    Enrollment closed • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • BMS-986156